ArticleDiabetes2014
GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats.
Article in Diabetes, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Trial
- β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.The Journal of clinical endocrinology and metabolism · 2015Trial
- Attenuated improvements in adiponectin and fat loss characterize type 2 diabetes non-remission status after bariatric surgery.Diabetes, obesity & metabolism · 2014Trial
- RYGB induces vagal sensory neuropathy characterized by altered Glp1r expression and enhanced exendin-4 responsiveness in male mice.American journal of physiology. Endocrinology and metabolism · 2026Article
- Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis.Obesity surgery · 2025Article
- Mucosal and hormonal adaptations after Roux-en-Y gastric bypass.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2023Review
- The role of glucagon after bariatric/metabolic surgery: much more than an "anti-insulin" hormone.Frontiers in endocrinology · 2023Review
- Review
- Glucagon-like peptide-1, a matter of taste?Reviews in endocrine & metabolic disorders · 2021Review
- A pilot study about the development and characterization of a Roux en Y gastric bypass model in obese Yucatan minipigs.Scientific reports · 2021Article
- Factors Affecting Metabolic Outcomes Post Bariatric Surgery: Role of Adipose Tissue.Journal of clinical medicine · 2021Review
- Glucagon-Like Peptide-1: Actions and Influence on Pancreatic Hormone Function.Comprehensive Physiology · 2020Review
- Recent Advances in the Neurobiology of Altered Motivation Following Bariatric Surgery.Current psychiatry reports · 2019Review
- Rational Design of Hybrid Peptides: A Novel Drug Design Approach.Current medical science · 2019Review
- GLP-1 Limits Adipocyte Inflammation and Its Low Circulating Pre-Operative Concentrations Predict Worse Type 2 Diabetes Remission after Bariatric Surgery in Obese Patients.Journal of clinical medicine · 2019Article
- Hepatic Glucagon Receptor Signaling Enhances Insulin-Stimulated Glucose Disposal in Rodents.Diabetes · 2018Article
- Roux-en-Y Gastric Bypass Surgery-Induced Weight Loss and Metabolic Improvements Are Similar in TGR5-Deficient and Wildtype Mice.Obesity surgery · 2018Article
- Early Weight Loss Independent Effects of Sleeve Gastrectomy on Diet-Induced Cardiac Dysfunction in Obese, Wistar Rats.Obesity surgery · 2017Article
- Roux-en-Y Gastric Bypass Improves Hepatic Glucose Metabolism Involving Down-Regulation of Protein Tyrosine Phosphatase 1B in Obese Rats.Obesity facts · 2017Article
- Gastric Bypass-Related Effects on Glucose Control, β Cell Function and Morphology in the Obese Zucker Rat.Obesity surgery · 2016Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Several bariatric operations are currently used to treat obesity and obesity-related comorbidities. These vary in efficacy, but most are more effective than current pharmaceutical treatments. Roux-en-Y gastric bypass (RYGB) produces substantial body weight (BW) loss and enhanced glucose tolerance, and is associated with increased secretion of the gut hormone glucagon-like peptide 1 (GLP-1). Given the success of GLP-1-based agents in lowering blood glucose levels and BW, we hypothesized that an individual sensitivity to GLP-1 receptor agonism could predict metabolic benefits of surgeries associated with increased GLP-1 secretion. One hundred ninety-seven high-fat diet-induced obese male Long-Evans rats were monitored for BW loss during exendin-4 (Ex4) administration. Stable populations of responders and nonresponders were identified based on Ex4-induced BW loss and GLP-1-induced improvements in glucose tolerance. Subpopulations of Ex4 extreme responders and nonresponders underwent RYGB surgery. After RYGB, responders and nonresponders showed similar BW loss compared with sham, but nonresponders retained impaired glucose tolerance. These data indicate that the GLP-1 response tests may predict some but not all of the improvements observed after RYGB. These findings present an opportunity to optimize the use of bariatric surgery based on an improved understanding of GLP-1 biology and suggest an opportunity for a more personalized therapeutic approach to the metabolic syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.